19 results on '"Donatella Balducci"'
Search Results
2. All trans-retinoic acid modulates the procoagulant activity of human breast cancer cells
- Author
-
Anna Falanga, Donatella Balducci, Laura Russo, and Marina Marchetti
- Subjects
medicine.medical_specialty ,Time Factors ,Down-Regulation ,Estrogen receptor ,Antineoplastic Agents ,Apoptosis ,Breast Neoplasms ,Tretinoin ,Biology ,Thromboplastin ,chemistry.chemical_compound ,Cell Line, Tumor ,Internal medicine ,medicine ,Humans ,RNA, Messenger ,Blood Coagulation ,neoplasms ,Cell Proliferation ,Dose-Response Relationship, Drug ,Cell growth ,organic chemicals ,Hematology ,biological factors ,Cancer procoagulant ,Neoplasm Proteins ,Gene Expression Regulation, Neoplastic ,Cysteine Endopeptidases ,Endocrinology ,Receptors, Estrogen ,chemistry ,Tumor progression ,Cancer cell ,Cancer research ,Female ,Growth inhibition ,medicine.drug - Abstract
All trans-retinoic acid (ATRA) induces apoptosis and/or differentiation in solid tumors, including breast cancer, and has become a therapeutic tool in this disease. In human promyelocytic leukemia ATRA reduces the expression of cellular procoagulant activities (PCA), i.e. tissue factor (TF) and cancer procoagulant (CP). There are no studies on the effects of ATRA on the PCA of solid tumors, i.e. breast cancer cells. We analyzed different human breast cancer cell lines in order to: 1. characterize the expression of TF and CP; 2. evaluate whether these activities are affected by ATRA; and 3. verify whether a reduction in tumor cell procoagulants may occur in association to apoptosis and growth inhibition induced by ATRA. Two estrogen receptor positive (ER-positive; i.e. MCF7 and ZR75.1) and one estrogen receptor negative (ER-negative; i.e. MDA.MB.231) cell lines were included into the study. The results show that ATRA affected TF in a dose-dependent fashion only in ER-positive cell lines. In particular, at 1 uM ATRA, TF significantly (p < 0.05) decreased by 57%, 44% in MCF7, ZR75.1 cells, respectively. Differently the results show that ATRA dose-dependently affected CP expression in all three cell lines. Specifically, at 1 uM ATRA, CP significantly decreased by 44%, 50% and 25% in MCF7, ZR75.1, and MDA.MB.231. Only in ER-positive cell lines, there was a dose-dependent inhibition of cell growth that became statistically significant at 1 uM ATRA, which was associated to a slight but significant increase in the percentage of apoptotic cells. In conclusion, this study demonstrates for the first time that ATRA downregulates the expression of TF and CP in breast cancer cells. Due to the pivotal role of coagulation activation in tumor progression, the capacity of ATRA to affect also tumor procoagulants, in parallel to cell apoptosis, open new perspectives in tumor therapy.
- Published
- 2011
3. Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin
- Author
-
Tiziano Barbui, Marcella Pagnoncelli, Anna Falanga, Laura Russo, Marina Marchetti, Alfonso Vignoli, and Donatella Balducci
- Subjects
Vascular Endothelial Growth Factor A ,medicine.medical_specialty ,Angiogenesis ,Angiogenesis Inhibitors ,Pharmacology ,chemistry.chemical_compound ,Neoplasms ,Internal medicine ,Tumor Cells, Cultured ,medicine ,Humans ,Cell Proliferation ,Tube formation ,Matrigel ,Dalteparin sodium ,Heparin ,Cell growth ,business.industry ,Endothelial Cells ,Hematology ,Heparin, Low-Molecular-Weight ,Capillaries ,Endothelial stem cell ,Vascular endothelial growth factor ,Endocrinology ,chemistry ,business ,medicine.drug - Abstract
Clinical studies suggest a survival advantage in cancer patients receiving low molecular weight heparin (LMWH). A suggested mechanism for this beneficial effect may reside in the antiangiogenic activity of heparins.In this study we investigated whether two different LMWHs, i.e. enoxaparin and dalteparin, and unfractionated heparin (UFH), affect the angiogenic potential of human microvascular endothelial cells (HMEC-1) promoted by tumor cells.HMEC-1 cells were incubated with tumor cell conditioned media (TCM) derived from human breast cancer and leukemic cells (i.e. MCF-7, MDA.MB.231, and NB4 cell lines) or recombinant cytokines (i.e. VEGF, FGF-2, TNF-alpha) +/-heparins. Capillary-like tube formation in Matrigel and cell proliferation were evaluated.All three TCM induced a significant (p0.05) increase in total length of tubes formed by HMEC-1 in Matrigel. These increases were significantly counteracted (62 to 100% mean inhibition) by enoxaparin and dalteparin, but were significantly less affected by UFH. Similarly, the tube formation induced by standard VEGF, FGF-2, or TNF-alpha was 100% inhibited by enoxaparin, and 70-90% by dalteparin, whereas minor or no inhibition was observed with UFH. VEGF was the most active cytokine in TCM of both breast cancer and leukemic cells. EC proliferation was significantly increased by standard angiogenic factors, and slightly affected by breast cancer TCM (p=ns). The addition of heparins significantly counteracted the proliferative stimuli.These results support a major role for LMWH compared to UFH in inhibiting the proangiogenic effect exerted by tumor cells or purified angiogenic factors on microvascular endothelium.
- Published
- 2008
4. MRI helps depict clinically undetectable risk factors in advanced stage retinoblastomas
- Author
-
Sonia De Francesco, Matteo Bellini, Mauro Caini, Alfonso Cerase, Alessandro Rossi, Daniela Galimberti, Theodora Hadjistilianou, Sara Leonini, Pietro Piu, Paolo Toti, Donatella Balducci, Lucia Monti, Paolo Galluzzi, and Sandra Bracco
- Subjects
Male ,Pathology ,medicine.medical_specialty ,genetic structures ,Retinal Neoplasms ,Enucleation ,Eye ,Eye Enucleation ,Ophthalmoscopy ,Risk Factors ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Neoplasm Invasiveness ,Neoplasm Staging ,medicine.diagnostic_test ,business.industry ,Advanced stage ,Retinoblastoma ,Infant ,Magnetic resonance imaging ,Histology ,General Medicine ,Magnetic Resonance Imaging ,eye diseases ,Sclera ,medicine.anatomical_structure ,Child, Preschool ,Optic nerve ,Female ,Original Article ,sense organs ,Neurology (clinical) ,Choroid ,Nuclear medicine ,business ,Orbit - Abstract
This study compared high-resolution MRI with histology in advanced stage retinoblastomas in which ophthalmoscopy and ultrasonography did not give an exhaustive depiction of the tumour and/or its extension. MRI of orbits and head in 28 retinoblastoma patients (28 eyes) treated with primary enucleation were evaluated. Iris neoangiogenesis, infiltrations of optic nerve, choroid, anterior segment and sclera suspected at MR and histology were compared. Abnormal anterior segment enhancement (AASE) was also correlated with histologically proven infiltrations. Brain images were also evaluated. Significant values were obtained for: prelaminar optic nerve (ON) sensitivity (0.88), positive predictive value (PPV) (0.75) and negative predictive value (NPV) (0.71); post-laminar ON sensitivity (0.50), specificity (0.83), PPV (0.50) and NPV (0.83); overall choroid sensitivity (0.82), and massive choroid NPV (0.69); scleral specificity (1), and NPV (1). AASE correlated with iris neoangiogenesis in 14 out of 19 eyes, and showed significant values for: overall ON PPV (0.65), prelaminar ON sensitivity (0.65), and PPV (0.61), post-laminar ON NPV (0.64); overall choroid sensitivity (0.77), PPV (0.59) and NPV (0.73); scleral NPV (0.83); anterior segment sensitivity (1), and NPV (1). Odds ratios (OR) and accuracy were significant in scleral and prelaminar optic nerve infiltration. Brain examination was unremarkable in all cases. High-resolution MRI may add important findings to clinical evaluation of advanced stage retinoblastomas.
- Published
- 2015
5. V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules
- Author
-
Tiziano Barbui, Vittoria Guerini, Anna Falanga, Donatella Balducci, Alfonso Vignoli, Marina Marchetti, and Laura Russo
- Subjects
Adult ,Blood Platelets ,Male ,Cancer Research ,Granulocyte ,medicine.disease_cause ,Hemostatics ,Tissue factor ,hemic and lymphatic diseases ,Genetics ,medicine ,Inflammatory molecules ,Humans ,Platelet ,In patient ,Molecular Biology ,Aged ,Aged, 80 and over ,Mutation ,Janus kinase 2 ,biology ,Essential thrombocythemia ,Cell Biology ,Hematology ,Janus Kinase 2 ,Middle Aged ,medicine.disease ,medicine.anatomical_structure ,Amino Acid Substitution ,Immunology ,biology.protein ,Female ,Cell Adhesion Molecules ,Granulocytes ,Thrombocythemia, Essential - Abstract
This article evaluates patients with essential thrombocythemia (ET) to determine whether the V617F mutation in the JAK2 gene affects platelet hemostatic and adhesive molecules, platelet-polymorphonuclear leukocyte (PMN) interactions, and PMN-activation characteristics, as well as plasma hypercoagulation markers.Thirty-seven ET patients with V617F JAK2 mutation and 38 wild-type, and 50 healthy controls were studied.Platelets from overall ET patients, compared to controls, expressed significantly higher membrane tissue factor (TF) and P-selectin (p0.01) and lower CD41 and CD42b (p0.01). TF appeared significantly higher in the V617F JAK2 carriers compared to wild-type, and total platelet TF antigen levels confirmed the same result. The presence of circulating platelet/PMN aggregates was significantly greater in the JAK2-mutation carriers than in the wild-type and controls (p0.05). PMN surface activation and inflammatory markers (i.e., CD14, TF, CD11b, and leukocyte alkaline phosphatase [LAP]) were all significantly higher in ET versus control subjects, with CD14 and LAP being the highest in the JAK2 mutation carriers. Finally, a significant increase in plasma hypercoagulation markers was found in ET patients, and the only difference for the V617F JAK2 carriers was higher plasma thrombomodulin levels (p0.01). Differences in white blood cell and PMN count, platelet TF, PMN CD14, and LAP, and plasma thrombomodulin remained significant after multivariate analysis.These results show that a correlation exists between the presence of V617F JAK2 mutation and selected hemostatic activation variables.
- Published
- 2007
6. Differential effect of the low-molecular-weight heparin, dalteparin, and unfractionated heparin on microvascular endothelial cell hemostatic properties
- Author
-
Alfonso, Vignoli, Marina, Marchetti, Donatella, Balducci, Tiziano, Barbui, and Anna, Falanga
- Subjects
Dalteparin ,Hemostasis ,Heparin ,Microcirculation ,Humans ,Endothelium, Vascular ,Heparin, Low-Molecular-Weight ,Cells, Cultured - Abstract
Heparins, including unfractionated heparin (UFH) and low-molecular-weight heparins (LMWH), are glycosaminoglycans that are largely used as anti-thrombotic drugs. While the mechanisms of their anticoagulant actions in blood have been extensively studied, their effects on the hemostatic properties of the endothelium are still under investigation. The aim of this study was to compare the antithrombotic effects of a LMWH, i.e. dalteparin, with UFH on both microvascular (human microvascular endothelial cells [HMEC-1]) and macrovascular (human umbilical vein endothelial cells [HUVEC]) endothelial cells.Endothelial cells were incubated with dalteparin or UFH and exposed to an inflammatory stimulus (i.e. lipopolysaccharide [LPS]). The following parameters were evaluated: tissue factor (TF procoagulant activity, antigen and mRNA), tissue factor pathway inhibitor (TFPI), and thrombomodulin (TM).In HMEC-1 and HUVEC, both heparins inhibited LPS-induced endothelial cell TF expression. However, in HMEC-1, dalteparin was significantly more effective than UFH. Both heparins increased TFPI antigen release in HMEC-1 and HUVEC. Dalteparin also reversed LPS-induced reduction of TM in HMEC-1, while UFH did not.These data show that both dalteparin and UFH suppress inflammatory-mediated TF expression and increase the anticoagulant properties of macro- and micro-vascular endothelial cells. However, dalteparin has significantly greater effects than UFH in the microvascular endothelium, a site that plays a central role in many processes involved in inflammation and thrombosis.
- Published
- 2006
7. Clotting mechanisms and cancer: implications in thrombus formation and tumor progression
- Author
-
Anna, Falanga, Marina, Marchetti, Alfonso, Vignoli, and Donatella, Balducci
- Subjects
Clinical Trials as Topic ,Platelet Aggregation ,Fibrinolysis ,Anticoagulants ,Antineoplastic Agents ,Thrombosis ,Neoplasm Proteins ,Cysteine Endopeptidases ,Drug Delivery Systems ,Drug Design ,Neoplasms ,Thromboembolism ,Disease Progression ,Cytokines ,Humans ,Thrombophilia ,Neoplasm Metastasis ,Blood Coagulation ,Cell Adhesion Molecules - Abstract
Development of cancer is associated with activation of blood coagulation. The results of laboratory tests clearly demonstrate that fibrin formation and dissolution is continuously ongoing at different rates in these patients, who are at increased risk of secondary thrombosis. Notably, fibrin formation is also involved in the process of tumor spread and metastasis. The pathogenesis of the hemostatic disorders in cancer is complex and reflects the interaction of different mechanisms involving the activation of various hemostatic components, such as the coagulation and fibrinolytic systems, the vascular endothelium, leukocytes, and platelets. Tumor cells possess the capacity to interact with all of these components. Indeed they directly activate the coagulation cascade by producing their own procoagulant factors, or they can stimulate the prothrombotic properties of other blood cell components. Additional mechanisms of blood clotting activation are started by the initiation of antitumor therapies. In the last 10 years research studies have greatly improved our knowledge of tumor-promoted prothrombotic functions. Understanding the molecular basis of the underlying mechanisms may help to identify better-targeted strategies to prevent thromboembolism in cancer patients. Further, pharmacological modulation of malignant cell hemostatic properties may not only affect the tumor-associated thrombotic risk but may also leave open the possibility to interfere with the progression of the disease.
- Published
- 2005
8. All-trans retinoic acid modulates microvascular endothelial cell hemostatic properties
- Author
-
Marina, Marchetti, Alfonso, Vignoli, Maria Rosa, Bani, Donatella, Balducci, Tiziano, Barbui, and Anna, Falanga
- Subjects
Hemostasis ,Umbilical Veins ,Dose-Response Relationship, Drug ,Tetrahydronaphthalenes ,Receptors, Retinoic Acid ,Tumor Necrosis Factor-alpha ,Fibrinolysis ,Retinoic Acid Receptor alpha ,Thrombomodulin ,Down-Regulation ,Tretinoin ,Simian virus 40 ,Benzoates ,Capillaries ,Cell Line ,Thromboplastin ,Up-Regulation ,Tissue Plasminogen Activator ,Plasminogen Activator Inhibitor 1 ,Humans ,Endothelium, Vascular ,Cell Line, Transformed ,Skin - Abstract
All-trans retinoic acid (ATRA) is an anti-tumor agent capable of controlling the hypercoagulable state associated with malignancy. Among hemostasis-regulating functions, ATRA modulates the procoagulant and fibrinolytic properties of endothelial cells (EC) from large vessels (HUVEC). In this study we investigated whether ATRA may affect the same activities of EC derived from microvessels (HMEC-1 cell line).We studied the effects of ATRA on procoagulant (i.e. tissue factor, TF), fibrinolytic (i.e. tissue plasminogen activator and inhibitor, t-PA and PAI-1) and anticoagulant (i.e. thrombomodulin, TM) properties of HMEC-1, compared to HUVEC. The type of retinoic acid receptor (RAR) possibly involved was identified by using synthetic retinoid selective agonists or antagonists for RAR alpha, beta or gamma. The study was conducted with or without tumor necrosis factor (TNF)alpha to induce the expression of some endothelial hemostatic properties.ATRA significantly inhibited TNFalpha-induced TF expression in HMEC-1 as well as HUVEC. ATRA increased t-PA antigen without significantly affecting PAI-1 expression, and counteracted the TNFalpha-induced t-PA decrease in both types of EC. Accordingly, t-PA activity was significantly increased by ATRA, even in the presence of TNFalpha. Finally, ATRA upregulated TM, and prevented TNFalpha-induced TM downregulation. The study with selective RARs agonists and antagonists indicated that RARalpha played a major role in t-PA and TM modulation, whereas all three receptors were involved in TF downregulation.This study provides the first evidence that ATRA increases antithrombotic potential also in microvascular EC, a very relevant compartment for tumor- and/or antitumor therapy-associated vascular complications.
- Published
- 2003
9. PO-12 The prothrombotic and proangiogenic potential of microvascular endothelial cells induced by tumor cells is reduced by the low molecular weight heparin (LMWH) dalteparin
- Author
-
Monia Marchetti, Laura Russo, A. Falanga, Donatella Balducci, and Alfonso Vignoli
- Subjects
Chemistry ,medicine.drug_class ,Cancer research ,medicine ,Low molecular weight heparin ,Tumor cells ,Hematology - Published
- 2007
10. O.01b All trans-retinoic acid modulates the procoagulant activity of human breast cancer cells
- Author
-
Donatella Balducci, Monia Marchetti, Laura Russo, and A. Falanga
- Subjects
chemistry.chemical_compound ,chemistry ,Cancer cell ,Cancer research ,All trans ,Retinoic acid ,Hematology ,Human breast - Published
- 2011
11. PO-89 Analysis of the thrombin generation activity expressed by acute promyelocytic leukemia (APL) cells with and without treatment with arsenic trioxide (ATO) and all-trans retinoic acid (ATRA)
- Author
-
Monia Marchetti, Donatella Balducci, A. Falanga, E. Diani, and Laura Russo
- Subjects
chemistry.chemical_compound ,chemistry ,Acute promyelocytic leukemia apl ,Retinoic acid ,Cancer research ,All trans ,Hematology ,Arsenic trioxide ,Thrombin generation - Published
- 2010
12. Arsenic Trioxide (ATO) and All-Trans Retinoic Acid (ATRA) Differently Affect the Thrombin Generation Potential of Acute Promyelocytic Leukemia (APL) Cells
- Author
-
Donatella Balducci, Laura Russo, Marina Marchetti, Anna Falanga, and Erika Diani
- Subjects
Acute promyelocytic leukemia ,Chemistry ,Cellular differentiation ,Immunology ,Cell Biology ,Hematology ,medicine.disease ,Thrombomodulin ,Biochemistry ,Cancer procoagulant ,Tissue factor ,chemistry.chemical_compound ,Thrombin ,Differentiation therapy ,medicine ,Cancer research ,Propidium iodide ,medicine.drug - Abstract
Abstract 3986 Poster Board III-922 Introduction A deregulated expression of procoagulant and anticoagulant activities characterises the phenotype of APL cells and contributes to the coagulopathy of this disease. The APL molecular remission induced by differentiation therapy with ATRA or ATO significantly affects specific cellular hemostatic properties of APL blasts. It is not known whether these variations translate into a comparable reduction of the overall procoagulant activity of APL cells. In this study we characterize the overall APL cell hemostatic potential by the calibrated automated method (CAT), a standardized global assay which reflects the net results of pro- and anti-coagulant forces. The endogenous thrombin potential (ETP), measured as the area under the thrombin generation (TG) curve, is a good indicator of overall plasma prothrombotic and hemorrhagic tendency. We evaluated 1) the sensitivity of NB4 cell TG potential to treatment with ATRA or ATO; 2) the correlation of CAT parameters to the levels of two known procoagulants, i.e. tissue factor (TF) and cancer procoagulant (CP), and anticoagulants (i.e. thrombomodulin, TM) and 3) the association of global TG to cell differentiation, proliferation, and apoptosis/necrosis. Methods NB4 cells were incubated 24h with either 0.1 μM ATO, or 1 μM ATRA, or the combination 0.1 μM ATO/1 μM ATRA, or the vehicle (control). The TG potential of NB4 cells was evaluated in normal pool plasma (NPP) by CAT assay; TF by chromogenic, ELISA, and cytofluorimetric assays; TFmRNA by RT-PCR; CP activity by chromogenic assay; TM by ELISA, cell differentiation by cytofluorimetric analysis of surface CD11b expression; and cell apoptosis/necrosis by annexin V/propidium iodide staining. Results TG potential of control NB4 cells (1350±70 nM*min) was significantly higher compared to normal granulocytes (p Conclusions ATRA alone or in combination with ATO is more effective in reducing the NB4-associated TG potential compared to ATO alone. While the ATRA±ATO-induced reduction of NB4-TG potential is associated to a downregulation of procoagulant factors (i.e. TF and CP) and to a parallel increase of the anticoagulant TM, differently, the ATO-induced decrease of NB4-TG potential is associated with the downregulation of TF and CP, without TM modification. CAT is a reliable method to characterize the TG potential of APL cells, and is sensitive to cell pharmacological treatments. Studies are needed to confirm the utility of the CAT to understand the role of different TG phenotypes in predicting the APL coagulopathy. Disclosures: No relevant conflicts of interest to declare.
- Published
- 2009
13. Impact of V617F JAK2 Mutation on Monocyte Tissue Factor and Procoagulant Activity in Patients with Essential Thrombocythemia(ET) or Polycythemia VERA (PV)
- Author
-
Alfonso Vignoli, T. Barbui, Alessandro Rambaldi, Donatella Balducci, Laura Russo, Hugo ten Cate, Silvia Salmoiraghi, Marina Marchetti, Marina Panova-Noeva, and A. Falanga
- Subjects
medicine.medical_specialty ,Monocyte ,Immunology ,Cell Biology ,Hematology ,Biology ,medicine.disease ,Biochemistry ,Tissue factor ,Polycythemia vera ,medicine.anatomical_structure ,Endocrinology ,Thrombin ,Coagulation ,Internal medicine ,medicine ,Platelet ,Allele ,medicine.drug ,Whole blood - Abstract
Clinical data suggest an increased thrombotic risk in patients with ET or PV carrying the JAK2V617F mutation. Laboratory data from our group show that ET patients carrying the JAK2V617F mutation are characterized by an enhanced platelet and neutrophil activation status (Falanga et al, Exp Hem 2007) and blood coagulation activation (Marchetti et al, Blood 2008), as compared to JAK2 wild-type ET. Since monocytes significantly contribute to blood coagulation activation as an important source of circulating tissue factor (TF), in this study we aimed to characterize the prothrombotic phenotype of monocytes from ET and PV patients and to evaluate whether and to what extent it is influenced by the JAK2V617F mutation. Twenty-four ET patients (10 JAK2 wild-type; 14 JAK2V617F carriers with 2%–35% mutant allele burden), 27 PV patients (all JAK2V617F carriers, 16 with 9%– 44% and 11 with 60%–100% allele burden, respectively), and 20 age-matched healthy subjects (controls, C) were enrolled into the study. Monocyte-associated TF antigen was measured on the cell surface by whole blood flow-cytometry, in both basal condition and after in vitro stimulation by bacterial endotoxin (lypopolysaccharide, LPS), as well as in cell lysates by ELISA. Monocyte procoagulant activity was evaluated by the Calibrated Automated Thrombogram (CAT) as the capacity of isolated monocyte lysates to induce thrombin generation in normal pool plasma. In basal conditions, significantly (p50% allele burden (26.1±4.2%). The in vitro LPS stimulation significantly increased TF expression on monocytes from all study subjects and C compared to non-stimulated monocytes (p50% allele load. Thrombin generation induced by monocytes from ET and PV patients was significantly increased compared to controls, as determined by significantly higher thrombin peaks (ET=145±12, PV=142±17, C=72.2±5 nM), and quantity of thrombin generated in time, i.e. the endogenous thrombin potential (ETP) (ET=1143±34, PV=1074±64, C=787±58 nM*min). The JAK2V617F PV subjects with >50% allele burden presented with the highest thrombin generation capacity (peak= 184±34 nM; ETP= 1268±32 nM). Our data indicate that the expression of the JAK2V617F mutation in ET and PV patients may confer to monocytes a different hemostatic phenotype in terms of increased expression of surface TF and thrombin generation capacity. These findings are in agreement with the previous observation of a hypercoagulable state associated with this mutation and suggest a new mechanism linking hemostatic cellular phenotypic alteration to genetic dysfunction in patients with myeloproliferative disease.
- Published
- 2008
14. ACQUIRED RESISTANCE TO ACTIVATED PROTEIN C (APC) IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA (ET)
- Author
-
T. Barbui, Elisabetta Castoldi, H. ten Cate, Henri M. H. Spronk, Monia Marchetti, Jan Rosing, Donatella Balducci, and A. Falanga
- Subjects
Acquired resistance ,business.industry ,Essential thrombocythemia ,medicine ,Cancer research ,In patient ,Hematology ,business ,medicine.disease ,Protein C ,medicine.drug - Published
- 2007
15. PO-13 Low-molecular weight heparin (LMWH) bemiparin and ultra-low-MWH RO-14 inhibit lung, breast and leukemia cancer cell-induced endothelial angiogenesis
- Author
-
E. Cantalino, A. Falanga, Monia Marchetti, Laura Russo, Alfonso Vignoli, and Donatella Balducci
- Subjects
Leukemia ,Lung ,medicine.anatomical_structure ,medicine.drug_class ,Chemistry ,Angiogenesis ,Cancer cell ,medicine ,Cancer research ,Low molecular weight heparin ,Hematology ,medicine.disease - Published
- 2007
16. PO-33 Elevated levels of platelet and endothelial microparticles in patients with essential thrombocythaemia
- Author
-
A. Falanga, Anja Leyte, Marijke C. Trappenburg, M. van Schilfgaarde, Wim Terpstra, Donatella Balducci, and Monia Marchetti
- Subjects
business.industry ,Medicine ,Platelet ,In patient ,Hematology ,Pharmacology ,business - Published
- 2007
17. PO-25 Predictive value for VTE of hemostatic markers in patients with multiple myeloma receiving thalidomide
- Author
-
A. Falanga, Monica Galli, T. Barbui, Alfonso Vignoli, Monia Marchetti, Laura Russo, Donatella Balducci, and Alessandro Rambaldi
- Subjects
Thalidomide ,Oncology ,medicine.medical_specialty ,business.industry ,Internal medicine ,medicine ,In patient ,Hematology ,business ,medicine.disease ,Predictive value ,Multiple myeloma ,medicine.drug - Published
- 2007
18. PO-75 Thrombin generation in patients with essential thrombocythemia (ET)
- Author
-
Henri M. H. Spronk, T. Barbui, Jan Rosing, Monia Marchetti, H. ten Cate, Elisabetta Castoldi, A. Falanga, and Donatella Balducci
- Subjects
business.industry ,Essential thrombocythemia ,Medicine ,In patient ,Hematology ,Pharmacology ,business ,medicine.disease ,Thrombin generation - Published
- 2007
19. Distinct Hemostatic Profile of Leukocytes in Essential Thrombocythemia (ET) Carrying the JAK2 V617F Mutation
- Author
-
Anna Falanga, Alfonso Vignoli, Donatella Balducci, Tiziano Barbui, Vittoria Guerini, Marina Marchetti, Laura Russo, and Alessandro Rambaldi
- Subjects
medicine.medical_specialty ,P-selectin ,business.industry ,Essential thrombocythemia ,Immunology ,Cell Biology ,Hematology ,Fibrinogen ,medicine.disease ,Biochemistry ,Gastroenterology ,Pathogenesis ,Tissue factor ,Basal (phylogenetics) ,Internal medicine ,medicine ,Platelet ,business ,medicine.drug ,Whole blood - Abstract
The pathogenesis of the thrombotic diathesis of patients with ET is not completely clarified. Activation of polymorphonuclear leukocyte (PMN) occurs in these patients and is associated with a hypercoagulable state and increased number of circulating platelet/PMN aggregates. Further, increased procoagulant Tissue Factor (TF) expression in ET PMN is also reported. Recently, a gain-of-function JAK2 mutation (V617F) has been described in a high proportion of bcr/abl-negative myeloproliferative disorders. Specifically, in subjects with ET the mutation is present in about 50% of cases and retrospective data suggest an association with a higher rate of complications, including thrombosis. Aim of this study was to evaluate whether ET patients carrying the JAK2 mutation possess PMN with different hemostatic characteristics compared to ET subjects without JAK2 mutation and healthy controls. Twenty ET patients, 10 with and 10 without JAK2 mutation (median age: 50 years, range 32–61; platelet count: median 782 x 109/L, range 474–1,565 x 109/L), not receiving cytoreductive therapy (classified as low risk group), were included in the study; 16 age matched healthy subjects acted as controls. Expression of CD11b, TF and fibrinogen on PMN surface as well as PMN-platelet mixed aggregates (defined as the percentage of CD11b-positive PMN co-expressing a platelet-specific marker, i.e. CD42b or CD62P) were evaluated by whole blood flow-cytometry in both basal condition and after in vitro PMN stimulation by f-MLP. In washed isolated PMN samples the level of TF-mRNA was determined by RT-PCR. In basal conditions, significantly (p
- Published
- 2005
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.